Greatest International Antiinfective Trial With Avelox

GIANT - Greatest International Antiinfective Trial With Avelox®

The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Inclusion Criteria:

• Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin

Exclusion Criteria:

• Exclusion criteria must be read in conjunction with the local product information